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ABSTRACT 26 
 27 
R-loops are a major source of replication stress, DNA damage and genome 28 
instability, which are major hallmarks of cancer cells. Accordingly, growing 29 
evidence suggests that R-loops may also be related to cancer. Here we 30 
show that R-loops play an important role in the cellular response to 31 
trabectedin (ET743), an anticancer drug from marine origin and its derivative 32 
lurbinectedin (PM01183). Trabectedin and lurbinectedin induced RNA-DNA 33 
hybrid-dependent DNA damage in HeLa cells, causing replication 34 
impairment and genome instability. We also show that high levels of R-loops 35 
increase cell sensitivity to trabectedin. In addition, trabectedin led to 36 
transcription-dependent FANCD2 foci accumulation, which was suppressed 37 
by RNase H1 overexpression. In yeast, trabectedin and lurbinectedin 38 
increased the presence of Rad52 foci, a marker of DNA damage, in an R-39 
loop-dependent manner. In addition to providing new insights into the 40 
mechanisms of action of these drugs, our study reveals that R-loops could 41 
be targeted by anticancer agents. Given the increasing evidence that R-42 
loops occur all over the genome, the ability of lurbinectedin and trabectedin 43 
to act on them may contribute to enhance their efficacy, opening the 44 
possibility that R-loops might be a feature shared by specific cancers. 45 
Implications: The data presented in this study provide the new concept that 46 
R-loops are important cellular factors that contribute to trabectedin and 47 
lurbinectedin anticancer activity. 48 
 49 
50 
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 51 
Introduction 52 
 53 
Cancer therapy greatly relies on the use of small molecules that directly 54 
perturb the DNA metabolism. Trabectedin (ET743) is one of such molecules. 55 
It has been initially derived from the sea squirt Ecteinascidia turbinata and is 56 
now produced synthetically, being currently employed in therapy of patients 57 
with advanced soft tissue sarcoma (1) and platinum-sensitive ovarian cancer 58 
(2). Different derivatives of trabectedin have been synthesized, among them 59 
lurbinectedin (PM01183), which is presently under evaluation in phase II and 60 
III clinical trials. 61 
One of the most important features of the mechanism of action of 62 
trabectedin and lurbinectedin is their inhibitory effect on transcription of 63 
protein-coding genes that is mediated by different means. First, they 64 
preferentially bind to specific DNA triplets that are often present on 65 
transcription recognition sites. In this way they could directly prevent loading 66 
of transcription factors onto chromatin (3). Moreover, both drugs were shown 67 
to induce degradation of the RNA polymerase II (RNAPII) through the 68 
ubiquitin-proteasome pathway (4-8). Of note, these effects are also 69 
observed in tumor-associated macrophages (TAMs). Indeed, both drugs 70 
inhibit the transcription of selected cytokines (e.g. CCL2, IL6, IL8, PTX3) by 71 
TAMs abrogating their protumoral properties and modifying the tumor 72 
microenvironment (9, 10). 73 
Tumor cells are commonly associated with genome instability. One 74 
important natural source of instability is represented by R-loops, a three-75 
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stranded nucleic acid structure consisting of an RNA-DNA hybrid and the 76 
displaced single-stranded DNA of the original DNA duplex (11). This 77 
structure could fulfill physiological roles as it occurs during immunoglobulin 78 
class switching recombination, plasmid or mitochondrial DNA replication and 79 
transcription regulation. On the other hand, they are an important source of 80 
DNA damage, genome instability and replication stress, which relates R-81 
loops with a number of neurodegenerative disorders and cancer (12, 13). 82 
Interestingly, the loss of function of the breast cancer susceptibility genes 83 
BRCA1 and BRCA2, which have been shown to increase R-loops and R-84 
loop-dependent DNA damage (14, 15), is also associated with an increased 85 
sensitivity to trabectedin (16). In a similar way, dysfunctions of the Fanconi 86 
anemia pathway that increased sensitivity to such agent (5) also cause 87 
accumulation of R-loops (17, 18).  88 
In addition, there are some similarities between R-loops and trabectedin 89 
adducts worth being considered. The head-to-tail binding of three 90 
trabectedin molecules to three adjacent optimal DNA binding sites changes 91 
the DNA duplex conformation from the B-form to an intermediate between 92 
the A- and the B-form, which strongly resembles the conformation of an 93 
RNA-DNA hybrid (19). Moreover, R-loops that accumulate in the absence of 94 
the putative RNA-DNA helicases AQR or SETX require the action of 95 
Nucleotide Excision Repair (NER) to be processed into Double Strand 96 
Breaks (DSBs) (20) as well as trabectedin adducts (21). 97 
For these reasons, in this study we have further explored the mechanism 98 
of action of trabectedin and lurbinectedin, in particular whether it could be 99 
partially mediated or affected by R-loops. We show that the DNA damage 100 
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and replicative stress caused by trabectedin and lurbinectedin is indeed 101 
partially dependent on R-loops, as demonstrated by molecular and genetic 102 
assays using both human cell lines and the yeast Saccharomyces cerevisiae 103 
as a model eukaryotic system. Our findings suggest that R-loops could be 104 
targets of anticancer agents and given the evidence that R-loops occur all 105 
over the genome (22), this opens the possibility that tumoral cells that 106 
accumulate R-loops may be more suitable for trabectedin and lurbinectedin 107 
treatment.  108 
 109 
 110 
Materials and Methods 111 
 112 
Cell culture and treatments 113 
HeLa cells were purchased from ECACC (European Collection of Cell 114 
Cultures), HeLa-TR (24) and HeLa HB-GFP (14) were previously generated 115 
in our laboratory. All cell lines were maintained in DMEM medium, 116 
supplemented with 10% heat-inactivated fetal calf serum (FCS), cultured at 117 
37ºC in a humidified atmosphere containing 5% CO2 and routinely tested for 118 
Mycoplasma using MycoAlert Mycoplasma Detection Kit (Lonza). HeLa HB-119 
GFP cells medium was supplemented with doxycycline at the final 120 
concentration of 2 g/ml to induce HB-GFP expression. Specific genes were 121 
knocked down using ON-TARGET SMARTpool siRNA from Dharmacon. 122 
Transient transfection of siRNA was performed using DharmaFECT 1 123 
(Dharmacon) according to the manufacturer’s instructions. The following 124 
plasmids were used for transfection: pcDNA3 (Invitrogen) (RNH1-) and 125 
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pcDNA3-RNaseH1 (RNH1+), containing the full length RNase H1 cloned into 126 
pcDNA3 (23). Lipofectamine 2000 (Invitrogen, Carlsbad, CA) was used for 127 
plasmid transfection. Assays were performed 48h or 72h after transfection. 128 
Trabectedin (ET743) and lurbinectedin (PM01183) were provided from 129 
Pharmamar. Cordycepin (C3394) and Neocarzinostatin (N9162) were 130 
purchased from Sigma. 131 
 132 
Single cell electrophoresis 133 
Single cell electrophoresis or comet assays were performed as described 134 
using a commercial kit (Trevigen, Gaithersburg, MD, USA) following the 135 
manufacturer´s instructions. Comet tail moments were analyzed using Open 136 
Comet software. At least 100 cells were scored in each experiment to 137 
calculate the median of the tail moment, as reported (24). 138 
 139 
Cell proliferation 140 
HeLa cells were siRNA transfected to knock down the specified genes 141 
and plated in 96-well plate. Following 72 hours, cells were treated with 142 
increasing doses of trabectedin (ET743) for 24 hours and cell proliferation 143 
was measured by the WST-1 reagent (Roche) following the manufacture´s 144 
instructions. Absorbance was measured using microplate (ELISA) reader 145 
VARIOSKAN FLASH (Thermo) at 450 nm with a reference wavelength of 146 
690 nm. Absorbance values were normalized to the value of the untreated 147 
and represented as arbitrary units (A.U.).  148 
 149 
Antibodies 150 
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Antibodies anti-RNASEH1 (15606-1-AP) and anti-FANCD2 (sc-20022) 151 
anti-53BP1 (NB100-304) were purchased from Proteintech, Santa Cruz and 152 
Novus Biologicals, respectively. The S9.6 antibody was purified from the 153 
hybridoma cell line HB-8730. 154 
 155 
Immunofluorescence and EdU labelling 156 
Immunofluorescence was performed as previously described (25). 157 
Briefly, cells were fixed with 3.7% formaldehyde in PBS for 15 minutes, 158 
permeabilized with 0.5% Triton X-100 and blocked with 3% bovine serum 159 
albumin (BSA) in PBS for 1 hour. The coverslips were then incubated with 160 
primary antibodies diluted 1:500 in 3% BSA in PBS for 2 hours followed by 1 161 
hour incubation with 1:1000 diluted secondary antibodies and nuclei 162 
counterstaining with 1 g/ml DAPI in PBS. For FANCD2 immunolabelling, 163 
before fixation cells were pre-permeabilized with 0.25% Triton X-100 in PBS 164 
for 1 minute on ice. S9.6 immunofluorescence was performed as previously 165 
described (20). For the EdU labeling, cells were pulse-labeled with 10 M 166 
EdU for 20 minutes before fixation. EdU staining was performed with a Click-167 
iT EdU Alexa Fluor 555 Imaging kit (Invitrogen) according to manufacturer’s 168 
instructions. Random images were acquired with a 63X or 40X objective and 169 
foci or nuclear intensity were scored using the MetaMorph software. At least 170 
100 cells were scored for each condition. 171 
 172 
DNA combing 173 
DNA combing was performed as previously described (24). Briefly, DNA 174 
fibers were extracted from cells in agarose plugs immediately after CldU 175 
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labeling and were stretched on silanized coverslips. DNA molecules were 176 
counterstained with an autoanti-ssDNA antibody (DSHB, 1:500) and an anti-177 
mouse IgG coupled to Alexa 647 (A21241, Molecular Probes, 1:50). CldU 178 
and IdU were detected with BU1/75 (AbCys, 1:20) and an anti-rat IgG 179 
coupled to Alexa 488 (A21470, Molecular Probes, 1:50) or B44 (Becton 180 
Dickinson, 1:20) anti-BrdU antibodies and an anti-mouse IgG coupled to 181 
Alexa 546 (A21123, Molecular Probes, 1:50), respectively. DNA fibers were 182 
analyzed on a Leica DM6000 microscope equipped with a DFC390 camera 183 
(Leica). Data acquisition was performed with LAS AF (Leica). Fork velocity 184 
was calculated as previously described (26). Replication asymmetry was 185 
calculated by dividing (longest green tract –shortest green tract) by the 186 
longest tract in divergent CIdU tracks. 187 
 188 
Yeast ‘halo’ assay 189 
Yeast cells of the wild-type W303 or the rad52 strains were plated in 190 
presence of 0.003% SDS in order to increase yeast cell permeability. 191 
Afterwards, paper filter disks were placed on the agar plates and 3 µL of 192 
increasing amounts of trabectedin or lurbinectedin (or DMSO as carrier 193 
control) were spotted onto them. After 3 to 6 days cells growth was 194 
monitored, plates were scanned and the diameter of the growth inhibition 195 
halo was measured. 196 
 197 
Rad52 foci analysis in yeast cells 198 
Wild-type W303 yeast cells were transformed in plates containing 199 
doxycycline (at the final concentration of 10 g/ml in order to repress the 200 
 9 
expression of ectopic RNase H1) with pWJ1344 plasmid coding the RAD52-201 
YFP fusion protein (27) and with pCM189-RNH1 with the RNH1 gene under 202 
the tet promoter (28) or the empty vector pCM189 (29). Cells were grown 203 
overnight with medium SC-L-U (Complete medium SC: 0.17% yeast nitrogen 204 
base and 0.5% ammonium sulfate, 2% glucose, supplemented with amino 205 
acids; –L and -U indicate the absence of leucine and uracil respectively) 206 
containing 0.003% SDS and without doxycyclin. Mid-log cultures 207 
overexpressing RNase H1 or not, were treated with increasing doses of 208 
trabectedin or lurbinectedin during 2 hours at 30ºC with 200 rpm shaking. 209 
Following fixation with 2.5% formaldehyde in 0.1M KHPO at pH 6.4 for 10 210 
minutes, the cells were washed twice with KHPO 0.1M pH 6.6 and once with 211 
KHPO 0.1M pH 7.4. Cells were permeabilized with ethanol 80% for 10 212 
minutes and after centrifugation were resuspended in water containing DAPI 213 
at the final concentration of 1 g/ml to counterstain the nuclei. Rad52–YFP 214 
foci were scored in more than 200 nuclei from S-G2 mid-log cells, using a 215 
Leica DC 350F microscope. 216 
 217 
Statistical analysis 218 
Statistical significance was determined by t-tests or the Mann-Whitney 219 
test as specified. All tests performed were 2-tailed unless otherwise 220 
specified and three levels of statistical significance were considered: *p  ≤ 221 
0.05, **p ≤ 0.01 and ***p ≤ 0.001. 222 
 223 
 224 
Results 225 
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 226 
Trabectedin and lurbinectedin treatment increase transcription-227 
dependent DNA damage  228 
Trabectedin and lurbinectedin covalently bind to DNA, physically 229 
impeding transcription and other DNA metabolic processes. To explore the 230 
possibility that the DNA adducts formed by these drugs could induce 231 
transcription-dependent genome instability, we analyzed DNA damage foci 232 
accumulation in HeLa cells in which transcription was abrogated by 233 
treatment with cordycepin, a potent transcription inhibitor that halts RNA 234 
chain elongation. HeLa cells treated during 4 hours with 25 nM of 235 
trabectedin or lurbinectedin accumulated 53BP1 foci, a DSB marker (Fig. 1 236 
a). However, when transcription was previously shut off with cordycepin 237 
(added 1 hour earlier), 53BP1 foci were significantly reduced, suggesting an 238 
important role of transcription in the mechanism of action of these drugs. 239 
Next, we assayed whether RNA-DNA hybrids could be involved in the 240 
transcription-dependent DNA damage observed. Indeed, overexpression of 241 
RNase H1, which removes the RNA moiety of the hybrids, partially reduced 242 
the 53BP1 foci observed after trabectedin treatment, suggesting that part of 243 
the role of transcription in the mechanism of action of these drugs was 244 
associated with R-loops (Supplementary Fig. S1). In this case we exposed 245 
cells to a lower dose of trabectedin for longer (10nM during 6 hours) to better 246 
see the increase of 53BP1 foci. This longer treatment was not possible with 247 
cordycepin-mediated transcription shut off.  248 
Provided the known negative effect of transcription and RNA-DNA 249 
hybrids on replication fork (RF) progression we decided to analyze the 250 
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accumulation of FANCD2 foci, a central player of the Fanconi Anemia (FA) 251 
DNA repair pathway, as a way to measure repair events occurring at 252 
potential stalled forks. FA is a DNA repair pathway that works on stalled RFs 253 
and cells deficient in this pathway have also been shown to be more 254 
sensitive to trabectedin (5). The experiment was performed as described 255 
above for 53BP1 foci. Trabectedin and lurbinectedin caused a significant 256 
increase of FANCD2 foci that was completely reversed by cordycepin 257 
treatment (Fig. 1b), suggesting a key role of these drugs in transcription-258 
replication (T-R) conflicts. Since both drugs caused very similar phenotypes, 259 
consistent with an expected common mechanism of action, we focused the 260 
rest of the study mainly on trabectedin.  261 
FANCD2 foci accumulation approximately doubled after a longer 262 
exposure to trabectedin at lower dose and this increase was entirely rescued 263 
by RNase H1 overexpression (Fig. 1c). To assure that this suppression by 264 
RNase H1 was specific for trabectedin, we analyzed the effect of a different 265 
and well-establish genotoxic and antitumoral drug, neocarzinostatin (30), 266 
and we found that it also increased FANCD2 foci but this phenotype was not 267 
suppressed by RNase H1 overexpression (Supplementary Fig. S2). Given 268 
the observed connection of RNA-DNA hybrids and DNA damage with 269 
trabectedin and lurbinectedin treatment, we tested directly for the presence 270 
of RNA-DNA hybrids using the S9.6 antibody, which specifically recognizes 271 
these structures, by in situ immunofluorescence (IF). As can be seen in 272 
Supplementary Fig. S3, trabectedin and lurbinectedin did not cause a 273 
significant increase in the nuclear intensity of the S9.6 signal. Since these 274 
drugs significantly decrease transcription and therefore the overall RNA 275 
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levels (8, 31) it is unlikely that they concomitantly increase R-loop levels. 276 
Nonetheless, they could act by exacerbating their impact on replication and 277 
genome integrity. Consistently, both drugs affected nucleolus integrity, as 278 
deduced from a perturbed localization of the nucleolar marker nucleolin and 279 
by a smaller or fragmented appearance of nucleoli detected with the S9.6 280 
antibody. 281 
 282 
Trabectedin enhances R-loop-dependent replication impairment 283 
Trabectedin directly interacts with DNA, forming adducts and producing 284 
distortions of the double helix. Since R-loops impair replication progression 285 
(32-36) we analyzed the impact of trabectedin on DNA replication and 286 
whether this would be associated with the presence of RNA-DNA hybrids. 287 
For this, we first assessed DNA replication levels after trabectedin treatment, 288 
by measuring the amount of incorporated EdU, a thymidine analog. 289 
Trabectedin treatment strongly affected the rate of DNA synthesis in HeLa 290 
cells, leading to lower levels of EdU incorporation compared to untreated 291 
cells  (Fig. 2a). However, the percentage of cells in S phase (EdU-292 
incorporating cells) was not affected (Supplementary Fig. S4a). Importantly, 293 
overexpression of RNase H1, which by itself caused a slight decrease in 294 
EdU incorporation, partially rescued the phenotype of reduced DNA 295 
synthesis (Fig. 2a).  296 
Next, we used DNA combing to check for impairment of replication fork 297 
progression in single molecules. Using low trabectedin concentrations at 298 
which the replication fork velocity was not perturbed, the drug caused an 299 
increase in fork stalling, as determined by fork asymmetry, which was 300 
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significantly higher in trabectedin-treated versus non-treated cells (Fig. 2b). 301 
To know whether this effect was dependent on transcription, required for the 302 
co-transcriptional formation of RNA-DNA hybrids, we inhibited transcription 303 
using cordycepin. With this approach, all cells were exposed to the same 304 
treatment, something that was not possible after transfection with an RNase 305 
H1-overexpressing plasmid. We observed that treatment of cells with the 306 
transcription inhibitor cordycepin abolished the difference in fork asymmetry 307 
between trabectedin-treated and untreated samples. This result suggests 308 
that fork-stalling caused by trabectedin is linked to transcription.  Inhibition of 309 
transcription by cordycepin was detrimental for replication at higher doses of 310 
trabectedin, which per se provoked a reduction in the replication rate 311 
(Supplementary Fig. S4b). Thus, it was not surprising that the concomitant 312 
treatment with the two chemicals reduced further the DNA replication rate as 313 
assessed by EdU incorporation. However, since trabectedin can also inhibit 314 
transcription (31), it is possible that the effect on DNA replication has 315 
multiple causes that would require further investigation.  316 
Based on these observations, we infer that the replication obstacles 317 
posed by trabectedin treatment are partially dependent on RNA-DNA 318 
hybrids.  319 
 320 
RNA-DNA hybrid-accumulating cells are hyper-sensitive to trabectedin 321 
To better establish a functional link between RNA-DNA hybrids and 322 
trabectedin, we assayed the sensitivity to trabectedin of cells in which RNA-323 
DNA hybrids were stabilized by a hybrid-binding protein. For this purpose we 324 
took advantage of a stable cell line that expresses the chimeric protein HB-325 
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GFP, a fusion protein constituted by the hybrid binding (HB) domain of the 326 
RNase H1 enzyme and the green fluorescent protein (GFP). Under these 327 
conditions RNA-DNA hybrids are likely “stabilized” by the binding of the HB 328 
domain, thus retaining the R-loops in the cell, consistent with previously 329 
reported results from BRCA2-depleted cells (14). Interestingly, cells 330 
expressing the HB-GFP fusion protein were more sensitive to trabectedin as 331 
assessed by cell proliferation assays (Fig. 3, left panel), suggesting that cells 332 
with higher levels of R-loops can be made more susceptible to this 333 
anticancer agent. We next knocked down two cellular factors, THOC1 and 334 
BRCA2, previously shown to enhance RNA-DNA hybrids by either 335 
preventing their formation or by promoting their removal. Depletion of any of 336 
the two genes is associated with an increase in RNA-DNA hybrids formation 337 
(14). The lack of BRCA2 or THOC1 increased cellular sensitivity to 338 
trabectedin both in the absence of HB-GFP and in cells expressing HB-GFP 339 
(Fig. 3, middle and right panel), having THOC1 depletion a stronger effect.  340 
 341 
Trabectedin and lurbinectedin induce DNA breaks that are partially 342 
mediated by RNA-DNA hybrids in human cells. 343 
Next, we analyzed the effect of trabectedin treatment in cell proliferation 344 
and genome integrity in human cells in relation to R-loop accumulation. For 345 
this, HeLa cells were first transfected with a plasmid that leads to the 346 
overexpression of RNase H1 before being treated with trabectedin or 347 
lurbinectedin and analyzed by alkaline single cell electrophoresis (comet 348 
assay) for the accumulation of DNA breaks. As shown in Fig. 4, trabectedin 349 
and lurbinectedin increased DNA breaks, as expected. However, when cells 350 
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overexpressed RNase H1, breaks were significantly reduced in cells treated 351 
with 50 nM lurbinectedin for 2 hour. We evaluated H2AX foci formation, a 352 
molecular marker that in addition to DNA damage is also associated with 353 
replicative stress signaling. Trabectedin treatment increased H2AX foci 354 
accumulation (Supplementary Fig. S5a). In this case, however, RNase H1 355 
treatment increased further the H2AX foci, suggesting that a double 356 
treatment with trabectedin and RNase H1 leads to an additive replicative 357 
stress and DNA damage. Indeed, RNA-DNA hybrids are also important 358 
intermediates of normal DNA replication (for Okazaki fragment synthesis) 359 
and, consistently, a clonogenic assay revealed that survival of cells 360 
overexpressing RNase H1 at the time of treatment with increasing doses of 361 
trabectedin was reduced (Supplementary Fig. S5b). 362 
 363 
The RNA-DNA hybrid-dependent genome instability associated with 364 
trabectedin and lurbinectedin is evolutionary conserved. 365 
To investigate whether trabectedin and lurbinectedin interact with RNA-366 
DNA hybrids regardless of cell type and organism as a way to confirm that 367 
they target directly DNA metabolism, we asked whether similar DDR 368 
phenotypes could be reproduced in the eukaryotic model organism 369 
Saccharomyces cerevisiae. For this we first analyzed the effect of 370 
trabectedin. Replication impairment causes genome instability and Rad52 is 371 
used as a marker to detect instability in the form of the accumulation of DNA 372 
damage. To assess sensitivity to trabectedin and lurbinectedin, we used the 373 
“halo” assay. Different yeast strains were homogenously plated on YEPD-374 
rich medium plates, and then Whatman-paper disks soaked with increasing 375 
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concentrations of the tested drug were placed on top of the plate. After 376 
growth, halos of growth inhibition around the disks were formed with a 377 
diameter that correlates with the levels of toxicity of the drug. As can be 378 
seen in Fig. 5a, increasing concentrations of trabectedin lead to increased 379 
yeast sensitivity, as detected by the size of the halo of growth inhibition 380 
around the trabectedin spot. Importantly, this halo was largely increased in 381 
rad52 yeast strains inactivated for homologous recombination DSB repair 382 
in comparison with the wild-type strain, even at concentrations at which 383 
trabectedin had no effect on wild-type cells (Fig. 5a). This result suggests 384 
that recombinogenic DNA breaks accumulated after trabectedin treatment, 385 
consistent with previous reports (21). To confirm this, we analyzed 386 
recombinogenic DSBs by Rad52 foci, used as a way to detect DSB repair 387 
centers (27). Consistently, trabectedin caused a significant increase of 388 
Rad52 foci. Cells treated with 250 M trabectedin, showed a 3-fold increase 389 
in the percentage of cells with Rad52 foci compared to the untreated control 390 
(Fig. 5b). To assay whether Rad52 foci were dependent on RNA-DNA 391 
hybrids, RNAse H1 was overexpressed in yeast cells by transformation with 392 
an RNase H1-overexpressing plasmid. Notably, the increase in Rad52 foci 393 
was suppressed by RNase H1 overexpression (Fig. 5b and Supplementary 394 
Fig. S6a). These results indicate that trabectedin-induced breaks are linked 395 
to the accumulation of RNA-DNA hybrids also in yeast cells. 396 
Next, we assayed the effect of lurbinectedin on cell growth and genome 397 
instability using the assays described above for trabectedin. As can be seen 398 
in Fig. 5c, lurbinectedin affected yeast growth as determined by the size of 399 
the growth inhibition halo formed around the increasing concentrations of the 400 
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chemical spotted on Whatman filter papers. Again, this effect was 401 
significantly enhanced in rad52∆ strains, consistent with the idea that cell 402 
growth was impaired due to the accumulation of unrepaired DSBs. 403 
Accordingly, lurbinectedin treatment caused a 2-3-fold increase of cells with 404 
Rad52 foci compared to untreated cells and this phenotype was fully 405 
suppressed by RNase H1 overexpression (Fig. 5d and Supplementary Fig. 406 
S6a). The decreased amount of Rad52 foci after overexpression of RNase 407 
H1 in trabectedin- or lurbinectedin-treated cells, was not due to the reduction 408 
of the protein levels, as confirmed by western blot (Supplementary Fig. S6b). 409 
Consequently, lurbinectedin, as well as trabectedin, caused R-loop 410 
dependent genome instability both in yeast and in human cells. This finding 411 
suggests that their action is most likely common to many different cell types, 412 
since they target molecular pathways that are well conserved across 413 
evolution.  414 
 415 
Discussion 416 
 417 
Increasing evidence points out the role of RNA-DNA hybrids in the boost 418 
of genome instability and replication stress that are major hallmarks of 419 
cancer cells. This opens the possibility that such hybrids could occur at high 420 
levels in some tumor cells and consequently could be used as therapeutic 421 
targets. For this reason, it is of growing importance to address the 422 
relationship between R-loops and the action of anticancer agents. 423 
Trabectedin and lurbinectedin are two powerful drugs used in cancer 424 
treatment whose ability to block cell proliferation is linked to its potential to 425 
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cause DNA breaks and inhibit transcription. In this study, we show that 426 
trabectedin and lurbinectedin activities are favored by transcription and, at 427 
least partially, they might be enhanced by R-loops. Trabectedin and 428 
lurbinectedin treatment enhanced transcription-dependent genome instability 429 
and replication stress (Figs. 1 and 2). Exposure to trabectedin or 430 
lurbinectedin did not cause a global increase in R-loops as assayed by S9.6 431 
immunofluorescence (Supplementary Fig. S3). However, these drugs 432 
caused genome instability and replicative stress that were dependent on 433 
transcription and RNA-DNA hybrids both in yeast and human cells. These 434 
findings suggest that trabectedin and lurbinectedin toxicity is higher at sites 435 
undergoing active transcription and R-loop accumulation. 436 
It was previously demonstrated that trabectedin and lurbinectedin directly 437 
bind DNA, forming adducts (6) and distort the double helix. Here we showed 438 
that these DNA adducts compromise replication fork progression; indeed, we 439 
found that trabectedin caused a profound impairment of DNA synthesis (Fig. 440 
2a). To some extent, we can attribute this effect to R-loop formation, 441 
because RNase H1 overexpression partially suppressed this DNA synthesis 442 
defect. RNase H1 specifically cleaves the RNA strand of RNA-DNA hybrids 443 
therefore, overexpression of this endoribonuclease counteracts the 444 
accumulation of RNA-DNA hybrids. However, the rescue of the EdU 445 
incorporation defect by RNase H1 overexpression was mild, which suggests 446 
that only a subset of the trabectedin-induced replicative problems were 447 
mediated by RNA-DNA hybrids. Analysis of DNA replication at the single 448 
molecule level by DNA combing revealed that transcription inhibition with 449 
cordycepin reduces the increase in fork asymmetry provoked by trabectedin 450 
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exposure (Fig. 2b), consistent with the conclusion that R-loops contribute to 451 
fork stalling in trabectedin treated cells. In any case, we cannot exclude the 452 
possibility that the inhibition of transcription by trabectedin could contribute 453 
to RF asymmetry.  454 
R-loop-dependent replication problems caused by trabectedin are 455 
possibly counteracted by the Fanconi Anemia (FA) pathway. The FA 456 
pathway has a key role in balancing replication stress, in particular when 457 
inter-strand crosslinking agents such as Mitomycin C (MMC) cause 458 
replication fork blockage (37) and has been shown to limit R-loop 459 
accumulation and R-loop-dependent genome instability (17, 18). 460 
Interestingly, FA is critical for the integrity of common fragile sites (CFSs), 461 
since FANCD2, a central player of the FA pathway, is required for a safe 462 
replication through R-loop-accumulating CFSs (38). Here, we found an 463 
increased accumulation of FANCD2 foci after trabectedin treatment that, 464 
importantly, was fully rescued by RNase H1 overexpression (Fig. 1c). This 465 
phenotype was different to that caused by other genotoxic agents. Thus, 466 
contrary to trabectedin, overexpression of RNase H1 in cells treated with the 467 
radiomimetic agent neocarzinostatin (NCZ) exacerbated FANCD2 foci 468 
accumulation (Supplementary Fig. S2). This may be explained if FANCD2 469 
foci induced by NCZ are not RNA-DNA hybrid-dependent, and RNase H1 470 
overexpression causes an additional type of replication stress. This finding 471 
adds further support to the conclusion that trabectedin has a prominent and 472 
specific action on R-loops where it preferentially causes DNA damage and 473 
breaks able to block replication fork progression. Consistently, using a cell 474 
line system where R-loops were stabilized by the ectopic expression of the 475 
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RNA-DNA hybrid binding domain of the RNase H1 enzyme fused to GFP, 476 
and additionally increasing the basal levels of R-loop through the siRNA-477 
mediated depletion of THOC1 or BRCA2, we determined that cells with 478 
higher levels of R-loops were more sensitive to trabectedin treatment (Fig. 479 
3).  480 
Importantly, we were able to recapitulate the phenotype of R-loop-481 
dependent genome instability caused by trabectedin and lurbinectedin in 482 
yeast cells. Rad52 foci induced after treatment of either trabectedin or 483 
lurbinectedin were rescued by RNase H1 overexpression (Fig. 5). This result 484 
strongly suggests that the preferred action of these anti-tumoral agents on 485 
DNA is independent of the eukaryotic system or cell type, arguing strongly in 486 
favor of a preferential action on the R-loop-containing chromatin. In HeLa 487 
cells exposed to these agents, the RNA-DNA hybrid-dependent DNA 488 
damage phenotype was not so clear as it was in yeast cells. However, we 489 
were able to show by comet assay and 53BP1 immunofluorescence that the 490 
DNA damage induced by trabectedin or lurbinectedin was partially rescued 491 
by RNase H1 overexpression (Fig. 4 and Supplementary Fig. S1). Besides, 492 
we found that H2AX foci accumulation after trabectedin treatment was 493 
further increased in cells overexpressing RNase H1 (Supplementary Fig. 494 
S5a). However, even if phosphorylated H2AX on Ser139 is used as a DSB 495 
marker, it also denotes replication stress, since it is extended through a large 496 
chromatin domain as an early response to replication fork stalling in an ATR-497 
dependent process (39). RNase H1 overexpression could cause replication 498 
stress and instability, likely because it hampers replication by altering 499 
Okazaki fragment dynamics. Accordingly, DNA synthesis was impaired in 500 
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cells overexpressing RNase H1 (Fig. 2a). The double treatment with RNase 501 
H1 overexpression and trabectedin might have an additive effect by their 502 
impact on replication, enhancing the probability of ssDNA gaps or breaks 503 
that would lead to increased cell death (Supplementary Fig. S5b). 504 
The novel finding of an interplay between R-loops and trabectedin in 505 
genome instability induction, is of particular interest because it could be 506 
exploited for cancer cells in which R-loops might be a common feature. The 507 
observation that trabectedin toxicity is augmented by the dysfunction in 508 
pathway that have been shown to protect both from cancer and from R-loops 509 
accumulation, such as the Fanconi anemia pathway and the BRCA1 and 510 
BRCA2 tumor suppressor genes (14, 15, 17, 18), supports the idea that R-511 
loops might be a hallmark of specific types of cancer (40). It has been shown 512 
that cancer patients with BRCA mutations exhibit improved clinical response 513 
to trabectedin (16). It would be interesting in the future to check if R-loops 514 
are increased in tumoral cells derived from such patients to strengthen our 515 
hypothesis that a subset of tumors characterized by an higher accumulation 516 
of R-loops are more suitable to be treated with trabectedin. 517 
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FIGURE LEGENDS 664 
 665 
Fig. 1. Trabectedin and lurbinectedin treatment increased transcription-666 
dependent 53BP1 and FANCD2 foci  667 
(a and b) Immunodetection of 53BP1 and FANCD2 foci in HeLa cells treated 668 
with trabectedin (ET743 or ET), lurbinectedin (PM01183 or PM) or left untreated 669 
(Unt) as indicated. Cells were or were not pretreated with cordycepin 50 M 670 
(CORD- or CORD+) during 1 hour and during the following 4 hours of 671 
treatment. Representative images and quantification are shown. Bars represent 672 
the averages  SEM of the percentage of cells with more than 5 foci from at 673 
least 3 independent experiments. (c) HeLa cells were transfected with the 674 
RNase H1 overexpression plasmid (RNH1+) or with the empty vector (RNH1-). 675 
Following 24 hours after transfection cells were treated with trabectedin (ET743) 676 
as indicated. After the incubation with ET743 cells were fixed and 677 
immunodetection of FANCD2 was performed. Representative images and 678 
quantification of cells with more than 5 FANCD2 foci in cells positive for RNase 679 
H1 overexpression are shown. Bars represent the averages  SEM of the 680 
percentage of cells with more than 5 foci from 5 independent experiments. 681 
Statistical significance was assessed by Student’s t-test. 682 
 683 
Fig. 2. Trabectedin treatment caused R-loop dependent replication 684 
impairment 685 
(a) HeLa cells were transfected with a plasmid built to overexpress RNase H1 686 
(RNH1+) or with the empty vector (RNH1-). Following 24 hours after 687 
transfection cells were treated with trabectedin (ET743) as indicated and pulse 688 
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labelled with EdU before fixation. Representative images from the cells labelled 689 
for EdU and RNase H1. Distribution of EdU nuclear intensity in cells positive for 690 
EdU (in RNH1- and in RNH1+ cells) and for RNase H1 overexpression (in 691 
RNH1+ cells) presented by a scatter dot plot where the median value is shown. 692 
The data from three independent experiments were pulled together. Differences 693 
between distributions were assessed by the Mann-Whitney test. (b) Outline of 694 
the experimental procedure followed before harvesting and processing HeLa 695 
cells for DNA combing. Distribution of replication fork velocity and asymmetry 696 
are presented by a scatter dot plot where the median value is shown. “Cord” 697 
indicates cordycepin. The data from four or two independent experiments were 698 
pulled together for fork velocity and asymmetry, respectively. Differences 699 
between distributions were assessed by the Mann-Whitney test.  700 
 701 
Fig. 3. HB-GFP cells showed increased sensitivity to trabectedin treatment 702 
HB-GFP cells (HB-GFP+) expressing the fusion protein HB-GFP or the parental 703 
cell line (HB-GFP-) were knocked down for the specified genes for 72 hours. 704 
After treatment with increasing doses of trabectedin (ET743) for 24 hours cell 705 
proliferation was measured by the WST-1 reagent. The graph shows the 706 
relative values of cell proliferation referred to the untreated sample at increasing 707 
doses of trabectedin. Averages  SEM from 10 independent experiments is 708 
presented. Statistical significance was assessed by paired t-test comparing for 709 
each siRNA the parental cells with the HB-GFP-expressing cell line. In the 710 
central and left graphs the dotted grey line represents the parental cells 711 
transfected by siC. 712 
 713 
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Fig. 4. Trabectedin and lurbinectedin caused R-loop dependent DNA 714 
damage 715 
HeLa cells were transfected with the RNase H1 overexpression plasmid  716 
(RNH1+) or with the empty vector (RNH1-). Following 48 hours after 717 
transfection cells were treated with trabectedin (ET743) (a) or lurbinectedin 718 
(PM01183) (b) as indicated and DNA damage levels were measured. 719 
Representative images from alkaline comet assays and quantification of the tail 720 
moment are shown. Bars represent the averages  SEM (Standard Error of the 721 
Mean) of the median from at least three independent experiments. Statistical 722 
significance was assessed by the one-tailed Mann-Whitney test.  723 
 724 
Fig. 5. Trabectedin or lurbinectedin treatment caused R-loop dependent 725 
genome instability in yeast cells 726 
(a) Representative images of halo assay performed in W303 and rad52 yeast 727 
cells and quantification of the inhibition halo diameter after the indicated 728 
trabectedin (ET743) treatments. Bars represent the averages  SEM from 4 729 
independent experiments. Statistical significance was assessed by Student’s t-730 
test. (b) Yeast cells W303 were transfected with Rad52-GFP plasmid and the 731 
RNase H1 overexpression plasmid (RNH1+) or with the empty vector (RNH1-) 732 
and treated with increasing amount of trabectedin. Bars represent the averages 733 
 SEM of the percentage of cells with one or more Rad52 foci from 3 734 
independent experiments. Statistical significance was assessed by Student’s t-735 
test. (c) Representative image of halo assay performed in W303 and rad52 736 
yeast cells and quantification of the inhibition halo diameter after the indicated 737 
lurbinectedin (PM01183) treatments. Bars represent the averages  SEM from 738 
 31 
4 independent experiments. Statistical significance was assessed by Student’s 739 
t-test. (d) Yeast cells W303 were transfected with Rad52-GFP plasmid and 740 
RNase H1 overexpression plasmid (RNH1+) or with the empty vector (RNH1-) 741 
and treated with increasing amount of lurbinectedin. Bars represent the 742 
averages  SEM of the percentage of cells with one or more Rad52 foci from 3 743 
independent experiments. Statistical significance was assessed by Student’s t-744 
test.  745 
 746 





